ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO957

Utility of Anti-PLA2R and Anti-THSD7A Antibodies in Predicting Membranous Nephropathy Recurrence: A Multi-Center Retrospective Cohort Study

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Hullekes, Frank E., Massachusetts General Hospital, Boston, Massachusetts, United States
  • Verhoeff, Rucháma, Massachusetts General Hospital, Boston, Massachusetts, United States
  • Cravedi, Paolo, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Riella, Leonardo V., Massachusetts General Hospital, Boston, Massachusetts, United States

Membranous nephropathy (MN) is a leading cause of nephrotic syndrome, frequently leading to kidney failure. The discovery of autoantibodies against podocyte antigens, including PLA2R and THSD7A, is a major advancement in our understanding of disease pathophysiology. The predictive value of PLA2R and THSD7A serum Abs in detecting recurrent MN remains undefined.


Through the Post-Transplant Glomerular Disease (TANGO) Consortium, we initiated a multi-center retrospective cohort study, investigating MN post-Tx, using clinical data and serum samples. Adults with biopsy-proven MN, transplanted between 2005-2021, were identified to study the predictive value of PLA2R and THSD7A in detecting recurrence.


22,921 patients were screened by 16 Tx centers across 3 continents. 86 kidney Tx recipients with biopsy-proven MN were included for anti-PLA2R Abs assessment. 46 patients were also screened for anti-THSD7A Abs. 37 patients (43%) developed recurrence at a median of 3.5 years (IQR: 1.5-6.1). Of these, 22 (59%) tested positive for anti-PLA2R Abs prior to recurrence. All 46 patients tested negative for anti-THSD7A Abs. The mean anti-PLA2R Abs for samples collected prior to recurrence was 136.9 RU/mL (95 CI: 55.7-218.2). These were taken with a median of 2.7 months (IQR: 12.9 – 0.1) before recurrence. Patients with recurrence had higher anti-PLA2R Ab than patients without (Figure 1A). Therapy consisted of RAAS inhibition for 30 patients (81%) and/or rituximab in 21 (56%) of the cases. After treatment, anti-PLA2R Abs notably decreased, with a mean of 13.9 RU/mL (95 CI: 3.7-24.1). These were taken with a median of 25.1 months (IQR: 4.0 – 54.6) after recurrence (Figure 1B).


The presence of anti-PLA2R antibodies may have predictive value in detecting recurrent MN post-transplant. Monitoring anti-PLA2R antibody levels and implementing appropriate therapies, in particular rituximab, could potentially aid in the management of recurrent MN.